Status:
TERMINATED
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Lead Sponsor:
Pfizer
Conditions:
Stroke
Eligibility:
All Genders
40-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.
Eligibility Criteria
Inclusion
- Males \& females age 40-90 years
- Enrolled in study within 6 hours of onset of stroke symptoms
- Willing to sign informed consent form
- No significant disabilities prior to stroke
Exclusion
- Treatment with t-PA (tissue plasminogen activator)
- Premorbid modified rankin scale score of 2 or more
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00073476
Start Date
September 1 2003
End Date
February 1 2005
Last Update
June 22 2006
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
La Mesa, California, United States, 91942
2
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
3
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46804
4
Pfizer Investigational Site
Fort Wayne, Indiana, United States, 46805